Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 Infection

Nanomedicine
Viruses
/References

Ipekoglu, Emre, Muzaffer Yildirim, Irem Evcili, Naz Yilmaz, Artun Bulbul, Nilsu Turay, Yagmur Aydin et al. "Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 Infection." Authorea Preprints (2021).

Background Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the 4 structural proteins of SARS-CoV-2. Methods VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography and characterized by tunable resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine. Results Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS-CoV-2. Alum adsorbed, K3-CpG ODN adjuvanted VLPs elicited high titer anti-S, anti-RBD, anti-N IgG, triggered multifunctional Th1 biased T cell responses, reduced virus load and prevented lung pathology upon live virus challenge in vaccinated animals. Conclusion These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.

View full article

Recent Publications

Surfactant-shell lipid nanocapsules (LNCs) are promising skin delivery systems. They are composed of an oily core with a stabilising shell of surfactant and phosphatidylcholine. LNCs’ hydrodynamic diameter can be easily tuned by varying the surfactant content in the formulation. Hydrophilic surfactants incorporated into LNCs have shown toxicity in mammalian cells. To date, the toxicity of all published surfactant-shelled LNCs produced by the the phase inverson temperature (PIT) method has been investigated using hydrophilic surfactants, with no studies examining the impact of incorporating hydrophobic surfactants on LNCs’ in vitro behaviour. Span 80 is a hydrophobic surfactant and has been extensively used in manufacturing various ranges of nanoparticles. The present study formulated Span 80-containing LNCs to evaluate their in vitro behaviour in the B16F10 melanoma cell line. LNC-100-S8 of Kolliphor HS15/Span 80 (65/35 w/w%) and original LNC100-0 LNCs of Kolliphor HS15 with a hydrodynamic diameter of 100 nm were prepared using the PIT method. A salt aggregation test confirmed increased surface hydrophobicity of LNC100-S8 compared to LNC100-0. Cytotoxicity assays demonstrated that LNC100-S8 had a three-fold lower cytotoxicity than LNC100-0 (IC80 = 11757 μg/mL vs 3184 μg/mL). Flow cytometry analysis indicated significantly higher cellular uptake of LNC100-S8 compared to LNC100-0, with 1.52-fold, 1.46-fold, and 1.67-fold increase at 1 h, 3 h, and 24 h, respectively . Mechanistic investigations revealed that LNC100-S8 uptake predominantly occured via phosphoinositide 3-kinase (PI3K)-regulated macropinocytosis and actin-dependent endocytosis, whereas LNC100-0 also utilised Na+/H+ exchanger-mediated macropinocytosis. Furthermore, protein corona analysis demonstrated increased interactions between LNC100-S8 and B16F10-conditioned media proteins, leading to bimodal size distribution and elevated polydispersity index (>0.3), which influenced their endocytic pathways. Overall, Our findings revealed the high promise of our Span 80-containing LNCs as a drug delivery system with enhanced cellular uptake and biocompatibility in B16F10 melanoma cells compared to conventional LNCs composed of Kolliphor HS15 surfactant, highlighting their potential uses in topical delivery to melanoma and other skin diseases.

2025